Net prices of new antiobesity medications

Abstract Objective Glucagon‐like peptide‐1 receptor agonists (GLP1s) are effective antiobesity drugs and the subject of intense debate around insurance coverage due to the large prevalence of obesity and overweight. The estimation of the budget impact associated with GLP1 insurance coverage requires estimates of GLP1 prices that account for manufacturer discounts. The authors applied a peer‐reviewed method to estimate the net prices of GLP1s after manufacturer discounts. Methods The authors estimated manufacturer discounts for each product as the difference between the gross sales estimated at list price and manufacturer‐reported revenue. From this difference, the authors subtracted discounts to government programs, including 340B, Medicaid, and the Medicare Part D coverage gap, and attributed the remaining amount to manufacturer discounts provided in the commercial market. Results Manufacturer discounts for GLP1s approved for obesity were estimated at 41%, which translated into net prices of 717 to 761 per month of supply. Manufacturer discounts for GLP1s approved for type 2 diabetes ranged from 54% to 59%, which translated into net prices of 312 to 469 per month of supply. Conclusions The magnitude of manufacturer discounts underscores the need to consider net price information in studies that inform private and public payers' decision‐making around coverage of GLP1s for obesity.